XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.4
Organization and Summary of Significant Accounting Policies - Narrative (Details)
9 Months Ended
Dec. 31, 2021
USD ($)
segment
shares
Dec. 31, 2020
USD ($)
Jan. 26, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of operating segments | segment 1    
Number of reporting segments | segment 1    
Amortization of operating lease right-of-use assets $ 1,250,000 $ 1,101,000  
Cash, cash equivalents and marketable securities $ 527,800,000    
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of shares owned (in shares) | shares 50,041,181    
Ownership percentage 53.40%    
Sumitomo Dainippon Pharma Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan | Majority Shareholder      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Available borrowing capacity $ 41,300,000    
Pfizer | Subsequent Event      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Outstanding payment from milestones achieved     $ 3,600,000,000
Richter | Subsequent Event      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Outstanding payment from milestones achieved     $ 122,500,000